Liver international : official journal of the International Association for the Study of the Liver · 2026
Liver Transplantation After Immune Checkpoint Inhibition in Hepatocellular Carcinoma-Data From the Multinational LITCHI Registry.
СтатьяМногоцентровое исследованиеНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bauer Ulrike, Troppmair Maria R, Khaled Najib Ben, Grottenthaler Julia M, Foerster Friedrich, Blümel Sena, Heinrich Sophia, Sinner Friedrich, Pinter Matthias, Hahn Magdalena, van Bömmel Florian, Scheiner Bernhard, Venerito Marino, Taubert Richard, Kremer Andreas E, Weinmann Arndt, Berg Christoph P, Lange Christian M, De Toni Enrico N, Djanani Angela, Zoller Heinz, Schmid Roland M, Ehmer Ursula
Аннотация
Evidence supporting the safety and efficacy of immune checkpoint inhibitors (ICI) before liver transplantation (LTx) in hepatocellular carcinoma (HCC) is increasing, but risks of graft rejection and tumour recurrence remain major concerns. We evaluated post-transplant outcomes across 10 European centres using data from the multinational LITCHI (Liver transplantation after immune checkpoint inhibition) registry. Clinical and tumour characteristics, ICI regimens and post-transplant immunosuppression were assessed, and overall and rejection-free survival were estimated using the log-rank test. Among 18 patients who underwent LTx following ICI, 15 were treated with atezolizumab plus bevacizumab. One-year survival was 77% (95% CI 67.3-87.8) and four rejection episodes occurred, with one fatal case after a 13-day wash-out and three non-fatal episodes, each responsive to escalation of immunosuppression. Overall, however, no intensified immunosuppression was required in our cohort. Despite tumour burden beyond Milan criteria in most patients before ICI initiation, HCC recurrence occurred in only one patient.